ABSTRACT
INTRODUCTION: While the presence of disseminated intravascular coagulation (DIC) has been implicated in worse clinical outcome in acute leukemia, the relationship between different subtypes of acute leukemia and the clinicopathologic features of DIC has not been systematically well studied. METHODS: In this study, we retrospectively reviewed 149 cases of newly diagnosed acute leukemia and assessed the utility of evaluating red blood cell morphologic features, and coagulation parameters in determining the presence of DIC as well as differentiating subtypes of acute leukemia. RESULTS: Review of our cohort demonstrates a novel finding, that elevated D-dimer concentrations ≥19 000 ng/mL fibrinogen equivalent units (FEU) are a sensitive diagnostic indicator of acute promyelocytic leukemia (APL) with moderate specificity, sensitivity 96%, specificity 92% in acute leukemia subtyping. Similar to other studies, APL showed an increased incidence of DIC (P < 0.01) compared to other subtypes of acute leukemia. Surprisingly, the presence of schistocytes on the peripheral blood smear was not a statistically significant indicator of DIC, sensitivity of 36% and specificity of 89%. Finally, the presence of DIC was not a significant indicator of poorer prognosis amongst all patients with AML. CONCLUSION: Overall we identify elevated D-dimer concentrations ≥19 000 ng/mL FEU are a sensitive indicator of acute promyelocytic leukemia (APL), with a sensitivity of 96% and specificity of 92% in the subtyping of acute leukemias, and that the presence of schistocytes in peripheral blood smears is not a diagnostically sensitive screening test for DIC with a sensitivity of 36%.
Subject(s)
Blood Coagulation , Disseminated Intravascular Coagulation/diagnosis , Disseminated Intravascular Coagulation/etiology , Fibrin Fibrinogen Degradation Products , Leukemia, Promyelocytic, Acute/blood , Leukemia, Promyelocytic, Acute/complications , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Biopsy , Blood Coagulation Tests , Chromosome Aberrations , Disseminated Intravascular Coagulation/mortality , Erythrocytes, Abnormal/pathology , Female , Humans , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/genetics , Leukocytes/pathology , Male , Middle Aged , Mutation , Prognosis , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Young AdultSubject(s)
Antineoplastic Agents/therapeutic use , Gene Rearrangement , Imidazoles/therapeutic use , Leukemia/drug therapy , Leukemia/genetics , Pyridazines/therapeutic use , Receptor, Fibroblast Growth Factor, Type 1/genetics , Acute Disease , Humans , Leukemia/pathology , Male , Middle Aged , Phenotype , PrognosisABSTRACT
INTRODUCTION: Heparin-induced thrombocytopenia (HIT) is a life-threatening condition, in which the anticoagulant heparin, platelet factor 4 (PF4), and platelet-activating antibodies form complexes with prothrombotic properties. Laboratory tests to support clinical diagnosis are subdivided into functional, platelet activation assays, which lack standardization, or immunological assays, which have moderate specificity toward HIT. In this study, clinical performance of HITAlert, a novel in vitro diagnostic (IVD) registered platelet activation assay, was tested in a large cohort of HIT-suspected patients and compared with immunological assays. METHODS: From 346 HIT-suspected patients (single center), clinical data including 4T pretest probability results, citrated platelet-poor plasmas, and sera were collected, allowing direct comparison of clinical observations with HITAlert results. HITAlert performance was compared with PF4 IgG ELISA (246 patients, three centers) and PF4 PaGIA (298 patients, single center). RESULTS: HITAlert showed high sensitivity (88.2%) and specificity (99.1%) when compared with clinical diagnosis. Agreement of HITAlert with PF4 ELISA- and PF4 PaGIA-positive patients is low (52.7 and 23.2%, respectively), while agreement with PF4 IgG ELISA- and PF4 PaGIA-negative patients is very high (98.1 and 99.1%, respectively). CONCLUSION: HITAlert performance is excellent when compared with clinical HIT diagnosis, making it a suitable assay for rapid testing of platelet activation due to anticoagulant therapy.
Subject(s)
Anticoagulants/adverse effects , Flow Cytometry , Heparin/adverse effects , Thrombocytopenia/chemically induced , Thrombocytopenia/diagnosis , Flow Cytometry/methods , Humans , Immunoglobulin G , Platelet Factor 4 , ROC Curve , Reproducibility of Results , Sensitivity and SpecificitySubject(s)
Biomarkers, Tumor/genetics , Ki-1 Antigen/metabolism , Leukemia, Large Granular Lymphocytic/genetics , Lymphoma, T-Cell/genetics , Mutation/genetics , STAT3 Transcription Factor/genetics , Aged , Bone Marrow/metabolism , Female , Follow-Up Studies , Humans , Lymph Nodes/metabolism , Male , Middle Aged , Prognosis , Skin/metabolismABSTRACT
Quantification of minimal residual disease (MRD) following allogeneic hematopoietic cell transplantation (allo-HCT) predicts post-transplant relapse in patients with chronic lymphocytic leukemia (CLL). We utilized an MRD-quantification method that amplifies immunoglobulin heavy chain (IGH) loci using consensus V and J segment primers followed by high-throughput sequencing (HTS), enabling quantification with a detection limit of one CLL cell per million mononuclear cells. Using this IGH-HTS approach, we analyzed MRD patterns in over 400 samples from 40 CLL patients who underwent reduced-intensity allo-HCT. Nine patients relapsed within 12 months post-HCT. Of the 31 patients in remission at 12 months post-HCT, disease-free survival was 86% in patients with MRD <10(-4) and 20% in those with MRD ≥10(-4) (relapse hazard ratio (HR) 9.0; 95% confidence interval (CI) 2.5-32; P<0.0001), with median follow-up of 36 months. Additionally, MRD predicted relapse at other time points, including 9, 18 and 24 months post-HCT. MRD doubling time <12 months with disease burden ≥10(-5) was associated with relapse within 12 months of MRD assessment in 50% of patients, and within 24 months in 90% of patients. This IGH-HTS method may facilitate routine MRD quantification in clinical trials.
Subject(s)
Immunoglobulin Heavy Chains/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Neoplasm, Residual/diagnosis , Neoplasm, Residual/genetics , Adult , Aged , Female , Follow-Up Studies , Hematopoietic Stem Cell Transplantation , High-Throughput Nucleotide Sequencing , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Male , Middle Aged , Prognosis , Recurrence , Reproducibility of Results , Time FactorsABSTRACT
T-cell large granular lymphocytic (LGL) leukemia is a complex diagnosis, requiring persistent clonal expansions of LGLs, and cytopenias. Often the diagnosis is unclear as non-clonal expansions of LGLs commonly occur in reactive conditions. To better understand T-LGL leukemia, we performed a comprehensive clinicopathologic analysis of 85 patients with LGL expansions. Interestingly, distinct CD8+(dim)/CD57+ populations, seen by flow cytometry, were significantly associated with clonal T-LGL leukemia (P < 0.001) as well as neutropenia (median absolute neutrophil count (ANC) 1.45 vs 3.19 × 10(9)/l; P = 0.0017). Furthermore, cases with distinct CD8+(dim)/CD57+ populations and monoclonal T cells had even lower ANCs (median ANC 1.41 × 10(9)/l; P = 0.001) compared with cases without these dual criteria. Additionally, complete or partial loss of CD5 expression was independently associated with clonal T-LGL leukemia (P<0.001) and neutropenia (median ANC 1.41 vs 2.70 × 10(9)/l; P = 0.002). This study describes specific immunophenotypic parameters to better define clonal cases of T-LGL leukemia associated with significant neutropenia.
Subject(s)
Leukemia, Large Granular Lymphocytic/diagnosis , Leukemia, Large Granular Lymphocytic/metabolism , Receptors, Antigen, T-Cell, alpha-beta/metabolism , T-Lymphocytes/metabolism , Adult , Aged , Aged, 80 and over , Clone Cells , Female , Flow Cytometry , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/genetics , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/immunology , Humans , Immune System/immunology , Immunophenotyping , Inflammation/diagnosis , Inflammation/immunology , Inflammation/metabolism , Leukemia, Large Granular Lymphocytic/immunology , Male , Middle Aged , Neutropenia/diagnosis , Neutropenia/immunology , Neutropenia/metabolism , Receptors, Antigen, T-Cell, alpha-beta/genetics , T-Lymphocytes/immunology , Young AdultABSTRACT
The eradication of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) predicts for improved outcome. However, the wide variety of MRD techniques makes it difficult to interpret and compare different clinical trials. Our aim was to develop a standardized flow cytometric CLL-MRD assay and compare it to real-time quantitative allele-specific oligonucleotide (RQ-ASO) Immunoglobulin heavy chain gene (IgH) polymerase chain reaction (PCR). Analysis of 728 paired blood and marrow samples demonstrated high concordance (87%) for patients off-therapy. Blood analysis was equally or more sensitive than marrow in 92% of samples but marrow analysis was necessary to detect MRD within 3 months of alemtuzumab therapy. Assessment of 50 CLL-specific antibody combinations identified three (CD5/CD19 with CD20/CD38, CD81/CD22 and CD79b/CD43) with low inter-laboratory variation and false-detection rates. Experienced operators demonstrated an accuracy of 95.7% (specificity 98.8%, sensitivity 91.1%) in 141 samples with 0.01-0.1% CLL. There was close correlation and 95% concordance with RQ-ASO IgH-PCR for detection of CLL above 0.01%. The proposed flow cytometry approach is applicable to all sample types and therapeutic regimes, and sufficiently rapid and sensitive to guide therapy to an MRD-negativity in real time. These techniques may be used as a tool for assessing response and comparing the efficacy of different therapeutic approaches.
Subject(s)
Flow Cytometry/standards , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Humans , Immunoglobulin Heavy Chains/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Neoplasm, Residual , Polymerase Chain Reaction/methods , Quality Control , Sensitivity and SpecificitySubject(s)
Factor V/genetics , Sequence Deletion , Animals , Blood Coagulation/genetics , COS Cells , Chlorocebus aethiops , Factor V/metabolism , Humans , Protein TransportSubject(s)
Abnormalities, Multiple/genetics , Chromosome Deletion , Chromosome Disorders/genetics , Chromosomes, Human, Pair 1 , Factor V Deficiency/genetics , Abnormalities, Multiple/blood , Adolescent , Blood Coagulation Tests , Chromosome Disorders/blood , Chromosome Disorders/complications , DNA Mutational Analysis , Factor V Deficiency/blood , Female , Humans , In Situ Hybridization, Fluorescence , Point Mutation , Severity of Illness Index , SyndromeABSTRACT
The molecular basis of Factor V deficiency has been defined in few patients only. We report a homozygous nucleotide change (G6395A) in two Tunisian probands with Factor V deficiency and bleeding episodes. This substitution results in the replacement of an arginine (R) by a histidine (H) in amino acid position 2074, located in the Factor V C2-domain. Mutations in this protein domain have not previously been described. Several lines of evidence support that this sequence variant is indeed disease causing: 1) Crystal structures of Factor V and molecular C2-domain modeling studies of H2074 suggest that the conserved R2074 is required for correct folding; 2) Structure-function studies of selective Factor V mutants (R2074A) demonstrate the importance of R2074 for structural stability of the Factor V C2-domain and for cofactor activity (1); 3) In Factor VIII, point mutations in codon 2209, which corresponds to position 2074 in Factor V, cause hemophilia A.
Subject(s)
Amino Acid Substitution , Factor V Deficiency/genetics , Factor V/genetics , Mutation, Missense , Point Mutation , Amino Acid Sequence , Consanguinity , Diseases in Twins , Factor V/chemistry , Female , Humans , Male , Models, Molecular , Molecular Sequence Data , Pedigree , Protein Conformation , Protein Structure, Tertiary , Sequence Alignment , TunisiaABSTRACT
Graft-versus-host disease (GVHD) complicating allogeneic bone marrow transplantation (BMT) is often attributed to mismatched minor histocompatibility antigens (mHags), which are poorly defined in humans. CD31 is a candidate human mHag relevant to acute GVHD, but reports disagree about its level of significance, the role of HLA restriction, and the relative importance of different polymorphic codons within the molecule. We therefore examined in greater detail the impact of CD31-matching on BMT outcome in a prospective study from a single institution. Samples of recipient and donor DNA were collected pretransplantation for all patients receiving unmanipulated bone marrow from an HLA-identical sibling over a 45-month period at our institution. CD31 DNA typing of alleles at the 3 polymorphic codons 125 (L or V), 563 (N or S), and 670 (R or G) was performed for 118 patient-donor pairs plus 2 additional pairs who had codon 125 typing only. Donor-recipient CD31 nonidentity was tested for correlation with BMT clinical outcome measures of severe acute GVHD, chronic GVHD, relapse, and survival. Gene frequencies of approximately 0.5 for each allele at all 3 codons were comparable to previous reports. Because complete association was seen for 563N with 670G and for 563S with 670R, nonidentity for those codons was analyzed as a single genetic marker designated codon 563/670. Donor-recipient CD31 nonidentity was a significant risk factor for overall survival, both at codon 563/670 (hazard ratio [hr] = 2.58, P = .005) and at codon 125 (hr = 1.07, P = .036). Similar results held for disease-free survival. Nonidentity at codon 563/670 was also a significant risk factor (odds ratio [OR] = 11.15, P = .011) for severe (grades III, IV) versus no (grade 0) acute GVHD. Nonidentity at codon 125 posed less but still significant risk (OR = 9.30, P = .030). When the comparison group without severe acute GVHD was expanded to include grade I as well as grade 0 patients, the risk from CD31 nonidentity increased for both codon 563/670 (OR = 12.31, P = .010) and codon 125 (OR = 11.24, P = .011). CD31 nonidentity remained a significant independent risk factor for survival and for severe acute GVHD when tested in multivariate analysis with the covariates of adulthood, recipient-donor sex difference, ethnic group, disease, pretransplantation risk category, HLA-A2 type, B44-like types, and GVHD prophylactic regimen. CD31 nonidentity showed a trend but failed to achieve statistical significance as a risk factor for relapse and for chronic GVHD. In conclusion, donor-recipient CD31 nonidentity is a significant risk factor for survival and for severe acute GVHD in HLA-identical sibling BMT. The stronger associations with codon 563/670 suggest that polymorphism may be more important than the linked polymorphism at codon 125.
Subject(s)
Bone Marrow Transplantation/immunology , Graft vs Host Disease/etiology , Histocompatibility , Minor Histocompatibility Antigens/analysis , Platelet Endothelial Cell Adhesion Molecule-1/analysis , Transplantation, Homologous/immunology , Acute Disease , Adolescent , Adult , Alleles , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/statistics & numerical data , Child , Chronic Disease , Codon/genetics , Disease-Free Survival , Female , Graft Survival/immunology , Graft vs Host Disease/epidemiology , HLA Antigens/analysis , HLA-B Antigens/analysis , HLA-B44 Antigen , Hematologic Neoplasms/mortality , Hematologic Neoplasms/therapy , Histocompatibility Testing , Humans , Immunosuppression Therapy , Life Tables , Male , Minor Histocompatibility Antigens/genetics , Multivariate Analysis , Nuclear Family , Platelet Endothelial Cell Adhesion Molecule-1/genetics , Polymorphism, Single Nucleotide , Prospective Studies , Risk Factors , Severity of Illness Index , Single-Blind Method , Survival Analysis , Transplantation, Homologous/adverse effects , Transplantation, Homologous/statistics & numerical data , Treatment OutcomeABSTRACT
BACKGROUND: It is unclear whether total serum homocysteine (tHcy) and the C677T mutation of methylenetetrahydrofolate reductase (MTHFR) are associated with cardiovascular disease (CVD) in patients with end-stage renal disease (ESRD). METHODS: A cross-sectional sample of 459 patients with ESRD on chronic dialysis was assessed to determine whether tHcy and the C677T mutation are associated with CVD prevalence in multiple logistic regression. As CVD mortality is high, we examined the relationship between homozygosity and duration of dialysis. RESULTS: Mean tHcy was higher in patients without a history of CVD (35.2 micromol/L vs. 30.4 micromol/L, P = 0.02). In multivariate models, CVD was negatively associated with tHcy and positively associated with TT genotype, male gender, and body mass index. Mean tHcy levels were higher among those with the TT genotype compared with those with the CC genotype when adjusted for age, folate, creatinine, and albumin (37.9 micromol/L vs. 31.9 micromol/L, P = 0.005). Among whites, the prevalence of the TT genotype was higher in those having undergone less than one year of dialysis (P = 0.002). CONCLUSIONS: The C677T genotype of MTHFR is associated with CVD in ESRD and may be a more meaningful marker than tHcy for abnormal homocysteine metabolism in ESRD. Prospective data from ongoing clinical trials are needed to improve our understanding of these findings. Screening for this polymorphism may help guide prevention measures.
Subject(s)
Cardiovascular Diseases/etiology , Hyperhomocysteinemia/complications , Kidney Failure, Chronic/complications , Oxidoreductases Acting on CH-NH Group Donors/blood , Body Mass Index , Cardiovascular Diseases/enzymology , Cardiovascular Diseases/genetics , Cross-Sectional Studies , Ethnicity , Female , Folic Acid/therapeutic use , Genotype , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/therapy , Male , Methylenetetrahydrofolate Reductase (NADPH2) , Middle Aged , Multivariate Analysis , Mutation , Oxidoreductases Acting on CH-NH Group Donors/genetics , Peritoneal Dialysis , Pyridoxine/therapeutic use , Renal Dialysis , Risk Factors , Sex Factors , Vitamin B 12/therapeutic useABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is characterized by a marked degree of morphologic and clinical heterogeneity. Establishment of parameters that can predict outcome could help to identify patients who may benefit from risk-adjusted therapies. BCL-6 is a proto-oncogene commonly implicated in DLBCL pathogenesis. A real-time reverse transcription-polymerase chain reaction assay was established for accurate and reproducible determination of BCL-6 mRNA expression. The method was applied to evaluate the prognostic significance of BCL-6 expression in DLBCL. BCL-6 mRNA expression was assessed in tumor specimens obtained at the time of diagnosis from 22 patients with primary DLBCL. All patients were subsequently treated with anthracycline-based chemotherapy regimens. These patients could be divided into 2 DLBCL subgroups, one with high BCL-6 gene expression whose median overall survival (OS) time was 171 months and the other with low BCL-6 gene expression whose median OS was 24 months (P =.007). BCL-6 gene expression also predicted OS in an independent validation set of 39 patients with primary DLBCL (P =.01). BCL-6 protein expression, assessed by immunohistochemistry, also predicted longer OS in patients with DLBCL. BCL-6 gene expression was an independent survival predicting factor in multivariate analysis together with the elements of the International Prognostic Index (IPI) (P =.038). By contrast, the aggregate IPI score did not add further prognostic information to the patients' stratification by BCL-6 gene expression. High BCL-6 mRNA expression should be considered a new favorable prognostic factor in DLBCL and should be used in the stratification and the design of risk-adjusted therapies for patients with DLBCL. (Blood. 2001;98:945-951)
Subject(s)
DNA-Binding Proteins/genetics , Lymphoma, B-Cell/diagnosis , Lymphoma, B-Cell/mortality , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/mortality , Proto-Oncogene Proteins/genetics , Transcription Factors/genetics , Adolescent , Adult , Aged , Biomarkers/analysis , DNA-Binding Proteins/standards , Disease-Free Survival , Gene Expression , Germinal Center/chemistry , Humans , Immunohistochemistry , Lymphoma, B-Cell/chemistry , Lymphoma, Large B-Cell, Diffuse/chemistry , Methods , Middle Aged , Polymerase Chain Reaction , Prognosis , Proto-Oncogene Mas , Proto-Oncogene Proteins/standards , Proto-Oncogene Proteins c-bcl-6 , Reproducibility of Results , Survival Rate , Transcription Factors/standardsABSTRACT
Follicle center lymphoma (FCL) accounts for approximately 40% of all non-Hodgkin's lymphomas (NHL). The genetic-environmental interactions involved in the etiology and pathogenesis of this disease are unknown. In our previous study a single nucleotide polymorphism (SNP) (397C) in the regulatory untranslated first intron region of the BCL-6 gene was found in four of the eight FCL patients but in none of the 10 healthy controls. To further evaluate the potential association between the 397C allele of the BCL-6 gene and FCL, we performed a case-control study. Genomic DNA was isolated from 85 FCL patients, from 98 control cases without a previous history of malignancy, treated at Stanford University Medical Center for non-malignant disorders and from 90 samples from the DNA Polymorphism Discovery Resource. The 397G and the 397C polymorphic alleles were identified by a PCR-RFLP method. To evaluate the possible effect of this polymorphism on gene expression, BCL-6 mRNA levels in nine FCL tumors with the 397G-G genotype and in nine FCL tumors with the 397G-C genotype were measured by quantitative real-time RT-PCR. The 397C polymorphic allele was found in 32 FCL cases (37.6%), in 20 controls (20.4%) and in 17 (18.9%) samples from the DNA Polymorphism Discovery Resource. The prevalence of the 397G-C and 397C-C genotypes was significantly higher in FCL cases than in control group (p = 0.01). No difference in BCL-6 gene expression was observed between FCL cases with 397G-G and 397G-C genotypes. The present study demonstrates a possible association between the 397C allele of the BCL-6 proto-oncogene and FCL. The similar levels of BCL-6 mRNA expression in 397G-G and in 397G-C FCL cases suggests that any possible oncogenic effect of the polymorphic allele would not simply be related to a direct effect on BCL-6 gene expression and suggests the existence of other FCL susceptibility genes that are in linkage disequilibrium with the 397C allele of the BCL-6 gene.
Subject(s)
DNA-Binding Proteins/genetics , Lymphoma, Follicular/genetics , Polymorphism, Genetic , Proto-Oncogene Proteins/genetics , Transcription Factors/genetics , Genotype , Humans , Proto-Oncogene Mas , Proto-Oncogene Proteins c-bcl-6 , RNA, Messenger/analysisABSTRACT
Molecular detection of a clonal population of B or T cells through analysis of rearranged antigen receptor genes is an essential adjunct to the morphologic, flow cytometric, and immunohistochemical evaluation of tissue specimens for the presence of leukemia or lymphoma. Combining polymerase chain reaction (PCR) with heteroduplex annealing and polyacrylamide gel electrophoresis (PAGE) has been used to detect clonal T-cell receptor rearrangements, particularly in skin biopsy specimens. The authors have developed a similar PCR heteroduplex assay for detection of clonal VDJ immunoglobulin gene rearrangements using two sets of primers based on relatively conserved consensus regions in the J(H) and framework I and 2 regions of the immunoglobulin heavy chain V region gene. This method is able to detect a clonal rearrangement when the clone comprises as little as 1% of the population in a polyclonal B-cell background. It may be used on fresh, frozen, or paraffin-embedded tissue and detects a clonal population in a majority of lymphoma subtypes. Compared with conventional PCR analysis, this method requires only a short additional cycle of denaturation and slow renaturation before PAGE. Interpretation is simplified as the clonal PCR product migrates away from the polyclonal background products.
Subject(s)
Frozen Sections , Gene Rearrangement, B-Lymphocyte/genetics , Gene Rearrangement, T-Lymphocyte/genetics , Heteroduplex Analysis/methods , Immunoglobulins/genetics , Paraffin Embedding , Polymerase Chain Reaction/methods , Antibodies, Monoclonal/genetics , Clone Cells , DNA Primers/genetics , Frozen Sections/methods , Immunoglobulins/isolation & purification , Leukemia, Lymphoid/genetics , Lymphoma, Non-Hodgkin/genetics , Paraffin Embedding/methods , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Sensitivity and SpecificityABSTRACT
We studied 14 cases that showed a morphologic appearance of peripheral T-cell lymphoma and contained substantial numbers of CD20+ large B cells. In all but 2 cases, the CD20+ large cells showed a mix of kappa and lambda light chain expression. Two cases showed a focal predominance of kappa expression. In situ hybridization using the EBER1 probe for detection of Epstein-Barr virus (EBV) RNA was performed on every case. EBV RNA was present in 10 cases. Of 8 cases with EBV RNA stained by immunohistochemistry for the latent membrane protein of EBV, 6 were positive. Double-labeling immunohistochemistry and in situ hybridization confirmed that EBV was present in the large B cells. Polymerase chain reaction (PCR) analysis showed a clonal rearrangement of the T-cell receptor (TCR)-gamma chain gene in 12 of 13 cases tested. One additional case showed a clonal rearrangement of the TCR-beta chain gene by Southern blot hybridization. PCR analysis showed a clonal immunoglobulin gene rearrangement in 5 cases, a suggestion of a clonal rearrangement in 1, an oligoclonal pattern in 4, and a polyclonal pattern in 4. The finding of large B and T cells may result in a misdiagnosis of a reactive process or of T-cell-rich B-cell lymphoma. The presence of EBV in some cases could cause further confusion with the reactive T- and B-immunoblastic proliferation of infectious mononucleosis.
Subject(s)
Lymphoma, B-Cell/complications , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, T-Cell, Peripheral/complications , Adult , Aged , Aged, 80 and over , Antigens, CD20/immunology , Blotting, Southern , DNA Primers/chemistry , DNA, Neoplasm/analysis , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/pathology , Epstein-Barr Virus Infections/virology , Female , Fluorescent Antibody Technique, Indirect , Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor/genetics , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/isolation & purification , Humans , Immunoglobulin kappa-Chains/genetics , Immunoglobulin lambda-Chains/genetics , In Situ Hybridization , Lymphoma, B-Cell/pathology , Lymphoma, B-Cell/virology , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Large B-Cell, Diffuse/virology , Lymphoma, T-Cell, Peripheral/pathology , Lymphoma, T-Cell, Peripheral/virology , Male , Middle Aged , Polymerase Chain Reaction , RNA, Viral/analysisABSTRACT
We developed a rapid, simple, and sensitive method for the detection of T-cell receptor-gamma (TCRgamma) gene rearrangements in paraffin-embedded skin biopsies. Available techniques often require either fresh tissue, several primer pairs, nested amplifications, or specialized electrophoresis steps such as denaturing gradient gel electrophoresis. Our method is based on heteroduplex analysis of polymerase chain reaction (PCR) products of the TCRgamma in a nondenaturing modified polyacrylamide gel using a single pair of primers and is adapted for paraffin-embedded tissue. When tested against Southern blot analysis, the PCR results correlated in 8 of 9 cases. Six mature cutaneous B-cell lymphomas and 29 inflammatory skin disorders all resulted in a polyclonal amplification pattern. When analyzing 3-mm or 4-mm punch biopsies of 51 cases of cutaneous T-cell lymphoma, 37 (72.5%) showed a clonal rearrangement with this technique. For 7 cases of patch stage mycosis fungoides, frozen tissue and formalin-fixed and paraffin-embedded tissue was available, and in 5 of 7 cases (71%), the results in frozen and paraffin-embedded tissue were concordant. One case showed a clonal pattern in frozen tissue but not in paraffin-embedded tissue, and one case was polyclonal in frozen tissue but monoclonal in paraffin-embedded tissue. Using serial dilutions of DNA from a T-cell ALL in a polyclonal background (tonsil), we established a sensitivity of 0.5%. Heteroduplex PCR of the TCRgamma is a rapid, sensitive, and inexpensive screening procedure as well as a useful adjunct to histologic analysis and immunophenotyping of cutaneous T-cell proliferations.